ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0343

Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Abstract Number: 0344

Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Abstract Number: 0345

Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Abstract Number: 0346

Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
Abstract Number: 0347

Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Abstract Number: 0348

Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
Abstract Number: 0349

Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
Abstract Number: 0350

Perioperative Evaluation of Blood Tests Including Bone Turnover Markers in Patients Undergoing Surgery for Proximal Femur Fractures
Abstract Number: 0351

Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
Abstract Number: 0352

Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Abstract Number: 0353

Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Abstract Number: 0354

Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
Abstract Number: 0355

Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Abstract Number: 0356

An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
Abstract Number: 0357

Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].